================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 23, 2004
Pharmion Corporation
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-50447 84-1521333
- ---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
2525 28th Street, Boulder, Colorado 80301
- ---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 720-564-9100
- --------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure
On February 23, 2004, Pharmion Corporation, a Delaware corporation (the
"Company"), issued a press release announcing that the Division of
Oncology Drug Products at the U.S. Food and Drug Administration ("FDA")
has accepted for review the Company's New Drug Application ("NDA") seeking
approval to market Vidaza(TM) (azacitidine for injectable suspension) for
the treatment of Myelodysplastic Syndromes (MDS). The press release also
announced that the FDA has designated the Company's NDA for "priority"
review. The press release is attached hereto as Exhibit 99.1 and
incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information And Exhibits
(c) Exhibits
99.1 Press Release, dated February 23, 2004, entitled "FDA Accepts
Pharmion's New Drug Application for Filing and Grants Priority Review for
Vidaza(TM) for the Treatment of Myelodysplastic Syndromes (MDS)."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMION CORPORATION
Date: 2/23/04 By: /s/ Erle T. Mast
-----------------------
Erle T. Mast
Chief Financial Officer
2